Main menu


Study: Some diabetes drugs reduce the risk of Alzheimer's disease

A new study confirmed that people who take certain medications to lower blood sugar for type 2 diabetes have less amyloid in the brain, which is a biomarker of Alzheimer's disease, according to the report published on the "Times of India" website.

The results of the study, published in the American Academy of Neurology, indicate that people taking these medications, known as dipeptidyl peptidase-4 inhibitors, showed less cognitive decline compared to people in the other two study groups.

Study author Phil Heo Lee, MD, from Yonsei University in Seoul, South Korea, said: 'Our study not only showed that people who took dipeptidyl peptidase-4 inhibitors to lower their blood sugar levels had less amyloid in their brains overall. It also showed lower levels in the areas of the brain involved in Alzheimer's disease."

The study included 282 people with an average age of 76, of whom 70 had diabetes who were treated with dipeptidyl peptidase-4 inhibitors, 71 had diabetes but were not treated with these drugs, and 141 were non-diabetics.

People without diabetes were matched with those with the disease for age, gender and education levels, and all had similar scores on cognitive tests at the start of the study.

Participants underwent brain scans to measure the amount of amyloid. The researchers found that people with diabetes who took the drugs had lower amounts of amyloid plaques that cause Alzheimer's disease, compared to people with diabetes who did not take those drugs and compared to people without the disease.

All participants took a combined test of thinking and memory, called the Mini Mental State Examination (MMSE), on average, every 12 months over a two-and-a-half year period.

Whereas those with diabetes who did not take the medication had an average annual decrease of 1.65 points, people without diabetes recorded an average annual decrease of 1.48 points.

The author of the study said: 'Our results show less amyloid in the brains of people taking diabetes medications and less cognitive decline, when compared to people without diabetes, raising the possibility that these drugs may also be beneficial for non-diabetic people who have problems with thinking and memory. ".

"More research is needed to establish whether these drugs may have neuroprotective properties in all people," he added.